Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
| Autor: | Eljack S; EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France.; Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Wadmedani, Sudan., David S; EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France., Faggad A; Department of Molecular Biology, National Cancer Institute, University of Gezira (NCI-UG), Wadmedani, Sudan., Chourpa I; EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France., Allard-Vannier E; EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, Tours, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of pharmaceutics: X [Int J Pharm X] 2022 Sep 06; Vol. 4, pp. 100126. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022). |
| DOI: | 10.1016/j.ijpx.2022.100126 |
| Abstrakt: | Chemoresistance and hence the consequent treatment failure is considerably challenging in clinical cancer therapeutics. The understanding of the genetic variations in chemoresistance acquisition encouraged the use of gene modulatory approaches to restore anti-cancer drug efficacy. Many smart nanoparticles are designed and optimized to mediate combinational therapy between nucleic acid and anti-cancer drugs. This review aims to define a rational design of such co-loaded nanocarriers with the aim of chemoresistance reversal at various cellular levels to improve the therapeutic outcome of anticancer treatment. Going through the principles of therapeutics loading, physicochemical characteristics tuning, and different nanocarrier modifications, also looking at combination effectiveness on chemosensitivity restoration. Up to now, these emerging nanocarriers are in development status but are expected to introduce outstanding outcomes. Competing Interests: The authors confirm that there are no known conflicts of interest associated with this publication, and there has been no significant financial support for this work that could have influenced its outcome. (© 2022 The Authors. Published by Elsevier B.V.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|